Pelage Pharmaceuticals
Los Angeles
About Pelage Pharmaceuticals
Pelage Pharmaceuticals develops regenerative medicine therapies focused on treating hair loss by reactivating dormant hair follicle stem cells. Its lead candidate, PP405, is a topical small molecule designed to modulate metabolic signaling in hair follicles so that inactive stem cells reenter the growth cycle. Pelage positions PP405 as a non-hormonal, non-invasive treatment intended to work across different genders, skin types, and hair types. The company is currently conducting Phase 2a clinical trials in androgenetic alopecia and aims to expand into other hair loss conditions. Its scientific team draws on work in stem cell biology and metabolic regulation and publishes its translational and clinical data in peer-reviewed channels.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $150.7M
- Funding stage: Early Stage Venture
- Last round: Series B (Oct 2025)
- Website: pelagepharma.com
- Phone: [email protected]
Industries & Categories
Health Care, Medical, Pharmaceutical, Therapeutics, Wellness
Social Profiles
Canonical: https://fsome.com/organization/pelage-pharmaceuticals-103164 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.